Literature DB >> 8135440

Mixed fluoxetine/loxapine overdose and atrial flutter.

R J Roberge1, T G Martin.   

Abstract

A 19-year-old man who attempted suicide by ingesting approximately 600 mg fluoxetine (Prozac) and 140 mg loxapine (Loxitane) had two episodes of atrial flutter shortly thereafter. Admission serum fluoxetine, norfluoxetine, and loxapine levels were 1,053 ng/mL, 702 ng/mL, and 40 ng/mL, respectively. This case of atrial flutter in association with an overdose of either of these drugs demonstrates the potential for cardiotoxicity with these agents in the overdose setting. Theoretical mechanisms of cardiotoxicity are presented.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8135440     DOI: 10.1016/s0196-0644(94)70083-4

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  5 in total

1.  Accidental ingestion of dosulepin presenting as atrial flutter in a child.

Authors:  Santabhanu Chakrabarti; James Fraser; Beverly Tsai-Goodman
Journal:  Eur J Pediatr       Date:  2009-04-05       Impact factor: 3.183

2.  Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes.

Authors:  János Magyar; Norbert Szentandrássy; Tamás Bányász; Valéria Kecskeméti; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-26       Impact factor: 3.000

Review 3.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

4.  Depression and coronary artery disease: the association, mechanisms, and therapeutic implications.

Authors:  Imran Shuja Khawaja; Joseph J Westermeyer; Prashant Gajwani; Robert E Feinstein
Journal:  Psychiatry (Edgmont)       Date:  2009-01

5.  A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers.

Authors:  James V Cassella; Daniel A Spyker; Paul P Yeung
Journal:  Int J Clin Pharmacol Ther       Date:  2015-11       Impact factor: 1.366

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.